share_log

Cybin | 6-K/A: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K/A: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K/A：外國發行人報告（業績相關）
美股SEC公告 ·  06/27 12:43
Moomoo AI 已提取核心訊息
Cybin Inc., a clinical-stage biopharmaceutical company, has filed an amended report with the SEC for June 2024, correcting an inadvertent incorporation by reference in its original Form 6-K and updating the date of a news release in the Exhibit Index. The company, which focuses on developing psychedelic-based treatments for mental health disorders, reported significant progress in its fiscal year 2024. Cybin received FDA Breakthrough Therapy Designation for CYB003, a psilocybin analog for Major Depressive Disorder, and completed site selection for a Phase 3 multinational study expected to begin in summer 2024. Cybin also initiated a Phase 2 study for CYB004, targeting Generalized Anxiety Disorder. Financially, Cybin reported a cash total of C$209 million as of March 31, 2024, and closed an oversubscribed private placement of U.S.$150 million. Despite these advancements, the company experienced an increased net loss of C$78 million for the year, compared to C$47 million the previous year. The company's CEO, Doug Drysdale, expressed optimism about the upcoming Phase 3 study and the potential impact of their treatments on mental health disorders.
Cybin Inc., a clinical-stage biopharmaceutical company, has filed an amended report with the SEC for June 2024, correcting an inadvertent incorporation by reference in its original Form 6-K and updating the date of a news release in the Exhibit Index. The company, which focuses on developing psychedelic-based treatments for mental health disorders, reported significant progress in its fiscal year 2024. Cybin received FDA Breakthrough Therapy Designation for CYB003, a psilocybin analog for Major Depressive Disorder, and completed site selection for a Phase 3 multinational study expected to begin in summer 2024. Cybin also initiated a Phase 2 study for CYB004, targeting Generalized Anxiety Disorder. Financially, Cybin reported a cash total of C$209 million as of March 31, 2024, and closed an oversubscribed private placement of U.S.$150 million. Despite these advancements, the company experienced an increased net loss of C$78 million for the year, compared to C$47 million the previous year. The company's CEO, Doug Drysdale, expressed optimism about the upcoming Phase 3 study and the potential impact of their treatments on mental health disorders.
臨床階段生物製藥公司Cybin Inc.已向美國證監會提交了第二份6-K表格，糾正原始6-K表格中不小心引用的問題，並更新了展示索引中新聞發佈日期的日期。該公司致力於開發基於致幻劑的治療心理健康障礙的療法，在其2024財年中取得了顯著進展。Cybin爲CYB003（一種用於重度抑鬱障礙的哌醋甲基色胺類似物）獲得FDA突破性療法認定，並完成了預計將於2024年夏季開始的大型3期多中心研究的個例篩選。Cybin還啓動了面向廣泛性焦慮障礙的CYB004的2期研究。財務上，Cybin於2024年3月31日報告了2.09億加元的現金總額，並關閉了一個超額認購的1.5億美元的定向增發。儘管取得了這些進展，該公司的淨虧損額在該年增加了7800萬加元，而上一年爲4700萬加元。該公司的首席執行官Doug Drysdale對即將到來的3期研究和他們治療心理健康障礙的潛在影響表示樂觀。
臨床階段生物製藥公司Cybin Inc.已向美國證監會提交了第二份6-K表格，糾正原始6-K表格中不小心引用的問題，並更新了展示索引中新聞發佈日期的日期。該公司致力於開發基於致幻劑的治療心理健康障礙的療法，在其2024財年中取得了顯著進展。Cybin爲CYB003（一種用於重度抑鬱障礙的哌醋甲基色胺類似物）獲得FDA突破性療法認定，並完成了預計將於2024年夏季開始的大型3期多中心研究的個例篩選。Cybin還啓動了面向廣泛性焦慮障礙的CYB004的2期研究。財務上，Cybin於2024年3月31日報告了2.09億加元的現金總額，並關閉了一個超額認購的1.5億美元的定向增發。儘管取得了這些進展，該公司的淨虧損額在該年增加了7800萬加元，而上一年爲4700萬加元。該公司的首席執行官Doug Drysdale對即將到來的3期研究和他們治療心理健康障礙的潛在影響表示樂觀。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息